Clinical Trials Logo

Filter by:
NCT ID: NCT01018758 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting

Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy

NHLPal
Start date: July 2006
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter phase II study in patients with aggressive Non Hodgkin Lymphoma scheduled to receive moderately emetogenic polychemotherapy (according to modified Hesketh classification for antiemetic therapy).

NCT ID: NCT01018706 Completed - Clinical trials for Myocardial Infarction

Goodness of Clinical History During Stemi PCI

GHOST
Start date: March 2010
Phase: N/A
Study type: Observational

The purpose of this study is to confirm or confute the hypothesis that in patients treated with primary pci is not always possible to collect an adequate medical history, the investigators created a clinical registry in which the investigators collect current or previous medical history relevant to DES utilization , in two distinct times.

NCT ID: NCT01018511 Completed - Clinical trials for Benign Prostatic Hyperplasia

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms

Neptune
Start date: January 2010
Phase: Phase 3
Study type: Interventional

Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS associated with BPH with a substantial storage component.

NCT ID: NCT01017952 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Start date: September 25, 2009
Phase: Phase 3
Study type: Interventional

The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)

NCT ID: NCT01017029 Completed - Clinical trials for Cardiac Transplantation

Everolimus in de Novo Heart Transplant Recipients

EVERHEART
Start date: September 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study, in de novo heart transplant patients, is to evaluate whether delayed introduction of everolimus reduces the occurrence of wound healing problems, pericardial and/or pleural effusion and early acute renal insufficiency, as compared with immediate introduction of everolimus, in the firs six months after heart transplantation.

NCT ID: NCT01016873 Completed - Clinical trials for Age-Related Macular Degeneration

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD

INTREPID
Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.

NCT ID: NCT01016509 Completed - Restenosis Clinical Trials

Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis

Start date: December 2009
Phase: N/A
Study type: Interventional

A multicentric study will evaluate whether peri-procedural tight glycemic control during angioplasty revascularization for acute coronary syndrome (ACS) reduces circulating inflammatory cytokines and thrombus formation in hyperglycaemic patients. Moreover, the investigators will assess whether the tight glycemic control during the first month from coronary event reduces the incidence of coronary stent restenosis at 6-months from PCI.

NCT ID: NCT01016496 Completed - Cerebral Palsy Clinical Trials

New Perspectives in the Rehabilitation of Children With Motor Disorders : the Role of the Mirror Neuron System

Start date: September 2009
Phase: N/A
Study type: Interventional

Evidence exists that the activation of actions activates the same cortical motor areas that are involved in the performance of the observed actions. The neural substrate for this phenomena is the mirror neuron system. It is generally assumed that mirror neurons have a basic role in understanding the intentions of others and in imitation learning. There is evidence that action observation has a positive effect on rehabilitation of motor disorders after stroke. The aim of this study is to demonstrate that action observation followed by the repetition of the actions previously observed has a positive impact on rehabilitation of the upper limb in children affected by hemiplegia as a consequence of Cerebral Palsy. In particular, the purpose is to assess if mirror neurons could improve the amount, the quality and the velocity of movements and the cooperation between the two upper extremities.

NCT ID: NCT01016392 Completed - Clinical trials for Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency

Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency

KAMPER
Start date: December 2009
Phase:
Study type: Observational [Patient Registry]

Kuvan® is a synthetic copy of a body's own substance called tetrahydrobiopterin (BH4). BH4 is required by the body to use an amino acid called phenylalanine in order to build another substance called tyrosine. Kuvan® received marketed authorisation in Europe in December 2008 and is now available in several European countries for the treatment of Hyperphenylalaninemia (HPA). The primary objective is to assess the long-term safety in subjects treated with Kuvan®. Secondary objectives are to provide additional information regarding: - Safety in specific subject groups (elderly, pediatric, pregnant women and subjects with renal or hepatic insufficiency). - Growth and neurocognitive outcomes for subjects with hyperphenylalaninemia (HPA) who are receiving treatment with Kuvan®. - Progress and outcome of pregnancy for women with HPA who become pregnant while receiving treatment with Kuvan® (these women will be enrolled in a dedicated sub-registry). - Assessment of adherence to diet and to Kuvan®. - Assessment of long-term sensitivity to Kuvan®treatment.

NCT ID: NCT01016366 Completed - Friedreich's Ataxia Clinical Trials

Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The primary purpose of the study is to determine whether carbamylated erythropoietin is a safe treatment for patients who suffer from Friedreich's Ataxia.